Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial
AUTOR(ES)
Svendsen, Kristina B
FONTE
BMJ Publishing Group Ltd.
RESUMO
Objective To evaluate the effect of the oral synthetic δ-9-tetrahydrocannabinol dronabinol on central neuropathic pain in patients with multiple sclerosis.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=498019Documentos Relacionados
- Randomised double blind controlled trial of cyclosporin in multiple sclerosis.
- Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea
- Hyperbaric oxygen and multiple sclerosis: final results of a placebo-controlled, double-blind trial.
- Intravenous immunoglobulin therapy in multiple sclerosis: progress from remyelination in the Theiler's virus model to a randomised, double-blind, placebo-controlled clinical trial.
- Double-blind, crossover, placebo-controlled clinical trial with clobetasol propionate in desquamative gingivitis
